Reply

Affiliations

Comment

Takahiro Kodama et al. Hepatology. 2022 May.

. 2022 May;75(5):1341.

doi: 10.1002/hep.32351. Epub 2022 Feb 11.

¹ Department of Gastroenterology and HepatologyOsaka University Graduate School of MedicineSuitaJapan.

No abstract available

Comment on

Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T. Kozumi K, et al. Hepatology. 2021 Nov;74(5):2452-2466. doi: 10.1002/hep.31995. Epub 2021 Aug 21. Hepatology. 2021. PMID: 34105780 Free PMC article.
Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
Lee CH, Lui DTW, Lam KSL. Lee CH, et al. Hepatology. 2022 May;75(5):1340. doi: 10.1002/hep.32353. Epub 2022 Feb 10. Hepatology. 2022. PMID: 35075677 No abstract available.

1. Lee C‐H, Seto W‐K, Lui D‐W, Fong C‐Y, Wan HY, Cheung C‐Y, et al. Circulating thrombospondin‐2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care. 2021;44:2089–97.
1. Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics identify thrombospondin‐2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74:2452–66.
1. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of non‐invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta‐analysis. Gut. 2021;1–14. https://doi.org/10.1136/gutjnl‐2021‐324243. - DOI